ARVO 2026: key results and trends
What the 4,943 abstracts at ARVO 2026 reported, drug by drug: the readouts that stood out and the targets and modalities that dominated.
- abstracts
- 4,943
- drug-linked abstracts
- 1,218
- companies
- 298
- from Phase 3 studies
- 70
Drug-linked abstracts by phase
- Phase 1 31
- Phase 1/2 13
- Phase 2 30
- Phase 2/3 5
- Phase 3 70
- Phase 4 7
Key results
Quotes are taken verbatim from each abstract's results; selection is automated. Report an issue
faricimab
Automated quantification of retinal fluid volume in patients with DME: analysis of faricimab vs aflibercept in YOSEMITE/RHINE
Read the abstract (opens in a new tab)Median time to first IRF volume <5 nL was week 72 for AFL Q8W after a median of 11 injections vs week 36 for FAR Q8W (hazard ratio [HR] 1.75 [95% CI: 1.49, 2.05]; P <0.0001) and T&E (HR 1.75 [95% CI: 1.49, 2.06]; P <0.0001) after a median of 7 and 6 injections, respectively.
ZVS101e
Interim Results of a Multicenter, Randomized, Controlled, Phase 3 Clinical Trial of a Single Subretinal Injection of ZVS101e in Patients with Bietti Crystalline Corneoretinal Dystroph
Read the abstract (opens in a new tab)The mean change in the MLMT score was 0.62 points in the treated group versus -0.44 points in the control group (p=0.017).
eflimrufusp alfa
Intravitreal RC28-E, a Recombinant Fusion Protein with Simultaneous Inhibition of Fibroblast Growth Factor-2 and Vascular Endothelial Growth Factor in patients with Diabetic Macular Edema: 52-week Results from a Randomized, Double-masked, Phase 3 Trial
Read the abstract (opens in a new tab)Analysis in moderately severe to severe non-proliferative diabetic retinopathy patients showed superior ≥3-step DRSS improvement with RC28-E vs aflibercept (27.8% vs 11.6% patients, respectively; nominal P = 0.0223).
aflibercept
Pigment epithelial detachment outcomes with aflibercept 8 mg versus aflibercept 2 mg in the PULSAR trial: A 96-week post hoc analysis
Read the abstract (opens in a new tab)At W96, the proportion of patients with serous PED decreased by 29.2% (2q8), 37.5% (8q12) and 36.7% (8q16) from BL, with fewer active injections with 8q12 and 8q16 versus 2q8 (9.7 and 8.2 vs 12.8) in the overall population.
pegcetacoplan
Earlier treatment yields better outcomes: 5 years of pegcetacoplan treatment for geographic atrophy secondary to AMD
Read the abstract (opens in a new tab)Eyes in the Early Treatment group demonstrated better outcomes: NSF GA growth was reduced by 31% with PM, preserving 3.87 mm 2 of retinal tissue (~2 disc areas), versus 26% and 1.93 mm 2 in the Delayed Treatment group.
avacincaptad pegol
Time-to-event analysis of driving eligibility maintenance following treatment with avacincaptad pegol in patients with geographic atrophy
Read the abstract (opens in a new tab)The risk probability of progressing to loss of driving eligibility in the study eye (≤60 letters) at 24 mths was 12.6% for ACP monthly or EOM vs 20.1% for sham, a 41% relative reduction in risk (hazard ratio [HR]: 0.59; 95% confidence interval [CI]: 0.34,1.02; nominal P =0.0594).
vamikibart
Efficacy and safety of vamikibart in combination with ranibizumab in patients with DME: first results from the phase 2 BARDENAS trial
Read the abstract (opens in a new tab)VAM+RBZ showed a statistically significant difference in the adjusted mean BCVA change from baseline at W44/48 of +12.8 letters versus +9.4 letters for RBZ ( P =0.063 with a pre-established nominal 0.1 significance level).
QA102
Oral QA102 Reduces Drusen Volume and Geographic Area Growth in Intermediate Atrophic Age-Related Macular Degeneration
Read the abstract (opens in a new tab)Compared to placebo, the mean change in drusen volume was reduced by 29.6% for subjects receiving QA102 200 mg (p=0.357) and 59.2% for QA102 400 mg (p=0.089).
tonabersat
Oral Tonabersat Connexin-43 Modulator for Eyes with Diabetic Macular Edema with Good Vision (DRCR Protocol AN)
Read the abstract (opens in a new tab)The mean (SD) change in CST from baseline to 6 months was -15 (55) µm in the tonabersat group and +5 (51) µm in the placebo group (adjusted mean difference: -16 [95% CI, -34 to 2], P=0.08).
vorolanib
VERONA phase 2 clinical trial of bioerodible EYP-1901 (vorolanib intravitreal insert) versus aflibercept for diabetic macular edema (DME): Visual, anatomic, and angiographic outcomes
Read the abstract (opens in a new tab)At W24, mean BCVA change from baseline was +7.1, +6.9, and +7.3 letters in the EYP-1901 2.7mg, 1.3mg, and afl arms, respectively.
IVW-1001
IVW-1001 ophthalmic eyelid wipe to treat dry eye patients, a Phase 1/2a Trial
Read the abstract (opens in a new tab)tCFS: 0.2% improved tCFS vs vehicle at Week 4 (study eye, p=0.0499) and Weeks 1–4 (fellow eye, p< 0.05).
Trends at ARVO 2026
Small molecules were the most frequent modality (59% of drug-linked abstracts). VEGFA was the most frequent target (15%). Exudative macular degeneration was the most frequent disease (11%).
What the abstracts covered
Share of the 1,218 drug-linked abstracts, by the target, modality, disease and company of each drug. An abstract can count in more than one row, so a list can add up to more than 100%.
- Bispecific antibodies8%93 drug-linked abstracts
Top targets
- VEGFA18815%
- VEGFB726%
- ANGPT2706%
- PGF706%
- GR534%
- C3b262%
- ESR1262%
- C3232%
- CHRM3222%
- CHRM4212%
Top modalities
- Small molecules71559%
- Non-antibody therapeutic proteins22418%
- Monoclonal antibodies20917%
- Bispecific antibodies938%
- Peptides938%
- Gene therapies726%
- Oligonucleotide and RNA therapeutics595%
- Carbohydrate, lipid and polymer therapeutics464%
Top diseases
- Exudative macular degeneration13411%
- Age-related macular degeneration (AMD)13111%
- Diabetic macular edema (DME)998%
- Glaucoma968%
- Dry eye syndrome (DED)645%
- Diabetic retinopathy (DR)615%
- Geographic atrophy (GA)595%
- Ocular hypertension534%
- Retinal atrophy464%
- Retinitis pigmentosa (RP)393%
Most active companies
- Roche817%
- Regeneron Pharmaceuticals706%
- Pfizer615%
- Merck393%
- Genentech373%
- Apellis Pharmaceuticals212%
- GSK212%
- AbbVie202%
- Alcon202%
- AstraZeneca192%
Explore every ARVO 2026 result in Gosset
All 1,218 drug-linked abstracts, joined to each drug’s trials, targets, developers and deals, with a source behind every line.
This page shows a sample of results. Gosset has the abstracts from this meeting and 100+ others; reach out for full access.